Gladell P. Paner, MD, (BS) MT
University of Chicago Uropathology Chicago, Illinois USA
ACTIONABLE NEW TRENDS IN URINARY BLADDER CANCER
The evolving world of bladder cancer has seen recent updates in its pathological classification, staging approaches, management, and integration of technological advances. With these waves of changes, the surgical pathologists must sufficiently funnel the information for implementation in their daily practice. This lecture is intended for general surgical pathologists and trainees interested in a perspective on the clinically actionable items in the recent advances in bladder cancer pathology. Discussion will cover the important variants of urothelial carcinoma, challenges and implications of contemporary staging criteria, use of novel and traditional immunohistochemical stains, and innovations in subtyping including genomic classification of bladder cancer.
“THEY DO LOOK ALIKE” - MIMICS OF PROSTATE CANCER IN BIOPSY SAMPLES
Prostate carcinoma is histologically unique for its wide spectrum of architectures and variant morphologies. However, this diversity in appearance is also complicated by an array of mimics such as benign structures and processes within the prostate, and their distinction can be challenging in needle biopsy samples. These mimics of cancer include benign glandular crowding, atrophy, hyperplasia, metaplasia, reactive atypia, inflammation, artifacts and non-prostatic histoanatomic structures. This lecture is designed for surgical pathologists to identify the patterns or variants of prostate carcinoma alongside their corresponding benign mimics. Hints on how to distinguish these two entities mainly by pattern-based approach will be provided. Use of selected immunohistochemical stains, where appropriate for optimal distinction, will also be provided.